Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Buserelin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Assessment of clinical efficacy and safety of HOE_766 (Buserelin) in treatment of patients with central precocious puberty.
    Active substance: Buserelin
    Study summary document link (including results):
    View full study record
    Document reference: 41847
    Study title: Assessment of clinical efficacy and safety of HOE_766 (Buserelin) in treatment of patients with central precocious puberty.
    Active substance: Buserelin
    Study summary document link (including results):
    View full study record
    Document reference: 41848
    Study title: Combined growth Hormone and Gonadotropin releasing Hormone analogue tretment in adopted girls with precocious or early puberty. Tuvemo et. Al 1998.Combined growth Hormone and Gonadotropin releasing Hormone analogue tretment in adopted girls with precocious or early puberty. Tuvemo et. Al 1998.
    Active substance: Buserelin
    Study summary document link (including results):
    View full study record
    Document reference: 41849
    Study title: Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormoneIntranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone - A.S. Luder et al. - 1984 (J. Clin. Endocrinol. Metab. ; 58: 966)
    Active substance: Buserelin
    Study summary document link (including results): Buserelin STUDY Luder 1984.xls
    View full study record
    Document reference: 41850
    Study title: Long-term results of GnRH analogue (buserelin) treatment in girls with central precocious pubertyLong-term results of GnRH analogue (buserelin) treatment in girls with central precocious puberty - R. Brauner et al. - 1985 (Acta Pediatr. Scand.; 74: 945)
    Active substance: BUSERELIN
    Study summary document link (including results): Buserelin STUDY Brauner.xls
    View full study record
    Document reference: 41851
    Study title:
    Active substance: BUSERELIN
    Study summary document link (including results):
    View full study record
    Document reference: 33742
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 17:00:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA